AAPL316.22+2.83 (+0.90%) ▲|ABBV249.91-2.83 (-1.12%) ▼|ABT94.40-0.78 (-0.82%) ▼|ACN139.06+3.50 (+2.58%) ▲|ADBE222.65+1.71 (+0.77%) ▲|AMAT588.66+18.16 (+3.18%) ▲|AMD546.72+29.32 (+5.67%) ▲|AMGN363.62-4.37 (-1.19%) ▼|AMT165.00-0.04 (-0.02%) ▼|AMZN247.04+3.42 (+1.40%) ▲|AVGO401.11+12.42 (+3.20%) ▲|AXP346.72+10.33 (+3.07%) ▲|BA223.11-1.84 (-0.82%) ▼|BAC59.25+0.95 (+1.63%) ▲|BKNG175.52+1.23 (+0.71%) ▲|BLK1,019.68+29.34 (+2.96%) ▲|BMY57.94+0.40 (+0.70%) ▲|BNY152.26+2.12 (+1.41%) ▲|BRK-B495.45+0.66 (+0.13%) ▲|C139.57+2.18 (+1.59%) ▲|CAT938.39-9.69 (-1.02%) ▼|CL91.01-2.03 (-2.18%) ▼|CMCSA23.35+0.16 (+0.67%) ▲|COF200.10+8.15 (+4.25%) ▲|COP108.02-2.70 (-2.44%) ▼|COST912.97-40.16 (-4.21%) ▼|CRM162.50-4.08 (-2.45%) ▼|CSCO118.31+4.49 (+3.94%) ▲|CVS102.81-1.66 (-1.59%) ▼|CVX174.05-1.92 (-1.09%) ▼|DE592.90-3.84 (-0.64%) ▼|DHR195.98+5.21 (+2.73%) ▲|DIS96.17-0.53 (-0.55%) ▼|DUK125.26-1.53 (-1.21%) ▼|EMR137.80+1.32 (+0.97%) ▲|FDX310.84+1.08 (+0.35%) ▲|GD374.60+0.29 (+0.08%) ▲|GE359.04+3.01 (+0.85%) ▲|GEV1,075.26+4.27 (+0.40%) ▲|GILD134.84-0.98 (-0.72%) ▼|GM76.65+0.41 (+0.54%) ▲|GOOG356.24-2.47 (-0.69%) ▼|GOOGL358.89-3.03 (-0.84%) ▼|GS1,055.97+26.33 (+2.56%) ▲|HD338.73+2.52 (+0.75%) ▲|HON223.42+3.06 (+1.39%) ▲|IBM295.30-6.75 (-2.23%) ▼|INTC112.54+2.30 (+2.09%) ▲|INTU273.38+1.28 (+0.47%) ▲|ISRG411.55-3.55 (-0.86%) ▼|JNJ259.10-4.30 (-1.63%) ▼|JPM335.47+4.85 (+1.47%) ▲|KO82.63-0.77 (-0.92%) ▼|LIN525.56-2.11 (-0.40%) ▼|LLY1,216.95+1.12 (+0.09%) ▲|LMT518.26-9.70 (-1.84%) ▼|LOW213.00+0.15 (+0.07%) ▲|LRCX353.17+20.02 (+6.01%) ▲|MA523.20+4.21 (+0.81%) ▲|MCD276.49-1.76 (-0.63%) ▼|MDLZ58.30-1.18 (-1.98%) ▼|MDT82.39+0.38 (+0.46%) ▲|META631.48+28.36 (+4.70%) ▲|MMM155.34+0.64 (+0.41%) ▲|MO71.59-1.22 (-1.68%) ▼|MRK125.07-0.92 (-0.73%) ▼|MS222.13+4.06 (+1.86%) ▲|MSFT384.36+1.02 (+0.27%) ▲|MU991.64+42.84 (+4.52%) ▲|NEE87.10-0.34 (-0.39%) ▼|NFLX75.47-0.12 (-0.16%) ▼|NKE42.78-0.11 (-0.26%) ▼|NOW108.84+1.06 (+0.98%) ▲|NVDA202.78-1.34 (-0.66%) ▼|ORCL144.22+3.73 (+2.66%) ▲|PEP137.86-4.64 (-3.25%) ▼|PFE24.25+0.20 (+0.83%) ▲|PG146.85-1.55 (-1.04%) ▼|PLTR129.04-3.18 (-2.41%) ▼|PM181.17-5.90 (-3.15%) ▼|QCOM191.11+4.55 (+2.44%) ▲|RTX195.20+0.29 (+0.15%) ▲|SBUX106.41+2.54 (+2.45%) ▲|SCHW101.91+0.21 (+0.21%) ▲|SO95.17-1.21 (-1.26%) ▼|SPG219.71+0.62 (+0.28%) ▲|T21.04-0.08 (-0.38%) ▼|TMO524.71+14.58 (+2.86%) ▲|TMUS181.48+1.34 (+0.74%) ▲|TSLA406.55+12.62 (+3.20%) ▲|TXN308.53+7.21 (+2.39%) ▲|UBER74.35+0.75 (+1.02%) ▲|UNH431.68+6.08 (+1.43%) ▲|UNP285.04+4.10 (+1.46%) ▲|UPS110.74+0.80 (+0.73%) ▲|USB61.90+0.90 (+1.48%) ▲|V348.20+0.67 (+0.19%) ▲|VZ42.24-0.21 (-0.49%) ▼|WFC86.91+1.35 (+1.58%) ▲|WMT112.21-0.89 (-0.79%) ▼|XOM137.46-3.67 (-2.60%) ▼|AAPL316.22+2.83 (+0.90%) ▲|ABBV249.91-2.83 (-1.12%) ▼|ABT94.40-0.78 (-0.82%) ▼|ACN139.06+3.50 (+2.58%) ▲|ADBE222.65+1.71 (+0.77%) ▲|AMAT588.66+18.16 (+3.18%) ▲|AMD546.72+29.32 (+5.67%) ▲|AMGN363.62-4.37 (-1.19%) ▼|AMT165.00-0.04 (-0.02%) ▼|AMZN247.04+3.42 (+1.40%) ▲|AVGO401.11+12.42 (+3.20%) ▲|AXP346.72+10.33 (+3.07%) ▲|BA223.11-1.84 (-0.82%) ▼|BAC59.25+0.95 (+1.63%) ▲|BKNG175.52+1.23 (+0.71%) ▲|BLK1,019.68+29.34 (+2.96%) ▲|BMY57.94+0.40 (+0.70%) ▲|BNY152.26+2.12 (+1.41%) ▲|BRK-B495.45+0.66 (+0.13%) ▲|C139.57+2.18 (+1.59%) ▲|CAT938.39-9.69 (-1.02%) ▼|CL91.01-2.03 (-2.18%) ▼|CMCSA23.35+0.16 (+0.67%) ▲|COF200.10+8.15 (+4.25%) ▲|COP108.02-2.70 (-2.44%) ▼|COST912.97-40.16 (-4.21%) ▼|CRM162.50-4.08 (-2.45%) ▼|CSCO118.31+4.49 (+3.94%) ▲|CVS102.81-1.66 (-1.59%) ▼|CVX174.05-1.92 (-1.09%) ▼|DE592.90-3.84 (-0.64%) ▼|DHR195.98+5.21 (+2.73%) ▲|DIS96.17-0.53 (-0.55%) ▼|DUK125.26-1.53 (-1.21%) ▼|EMR137.80+1.32 (+0.97%) ▲|FDX310.84+1.08 (+0.35%) ▲|GD374.60+0.29 (+0.08%) ▲|GE359.04+3.01 (+0.85%) ▲|GEV1,075.26+4.27 (+0.40%) ▲|GILD134.84-0.98 (-0.72%) ▼|GM76.65+0.41 (+0.54%) ▲|GOOG356.24-2.47 (-0.69%) ▼|GOOGL358.89-3.03 (-0.84%) ▼|GS1,055.97+26.33 (+2.56%) ▲|HD338.73+2.52 (+0.75%) ▲|HON223.42+3.06 (+1.39%) ▲|IBM295.30-6.75 (-2.23%) ▼|INTC112.54+2.30 (+2.09%) ▲|INTU273.38+1.28 (+0.47%) ▲|ISRG411.55-3.55 (-0.86%) ▼|JNJ259.10-4.30 (-1.63%) ▼|JPM335.47+4.85 (+1.47%) ▲|KO82.63-0.77 (-0.92%) ▼|LIN525.56-2.11 (-0.40%) ▼|LLY1,216.95+1.12 (+0.09%) ▲|LMT518.26-9.70 (-1.84%) ▼|LOW213.00+0.15 (+0.07%) ▲|LRCX353.17+20.02 (+6.01%) ▲|MA523.20+4.21 (+0.81%) ▲|MCD276.49-1.76 (-0.63%) ▼|MDLZ58.30-1.18 (-1.98%) ▼|MDT82.39+0.38 (+0.46%) ▲|META631.48+28.36 (+4.70%) ▲|MMM155.34+0.64 (+0.41%) ▲|MO71.59-1.22 (-1.68%) ▼|MRK125.07-0.92 (-0.73%) ▼|MS222.13+4.06 (+1.86%) ▲|MSFT384.36+1.02 (+0.27%) ▲|MU991.64+42.84 (+4.52%) ▲|NEE87.10-0.34 (-0.39%) ▼|NFLX75.47-0.12 (-0.16%) ▼|NKE42.78-0.11 (-0.26%) ▼|NOW108.84+1.06 (+0.98%) ▲|NVDA202.78-1.34 (-0.66%) ▼|ORCL144.22+3.73 (+2.66%) ▲|PEP137.86-4.64 (-3.25%) ▼|PFE24.25+0.20 (+0.83%) ▲|PG146.85-1.55 (-1.04%) ▼|PLTR129.04-3.18 (-2.41%) ▼|PM181.17-5.90 (-3.15%) ▼|QCOM191.11+4.55 (+2.44%) ▲|RTX195.20+0.29 (+0.15%) ▲|SBUX106.41+2.54 (+2.45%) ▲|SCHW101.91+0.21 (+0.21%) ▲|SO95.17-1.21 (-1.26%) ▼|SPG219.71+0.62 (+0.28%) ▲|T21.04-0.08 (-0.38%) ▼|TMO524.71+14.58 (+2.86%) ▲|TMUS181.48+1.34 (+0.74%) ▲|TSLA406.55+12.62 (+3.20%) ▲|TXN308.53+7.21 (+2.39%) ▲|UBER74.35+0.75 (+1.02%) ▲|UNH431.68+6.08 (+1.43%) ▲|UNP285.04+4.10 (+1.46%) ▲|UPS110.74+0.80 (+0.73%) ▲|USB61.90+0.90 (+1.48%) ▲|V348.20+0.67 (+0.19%) ▲|VZ42.24-0.21 (-0.49%) ▼|WFC86.91+1.35 (+1.58%) ▲|WMT112.21-0.89 (-0.79%) ▼|XOM137.46-3.67 (-2.60%) ▼|
26 C
New York
Thursday, July 9, 2026

Tag: risk

newssourceFORcompanyinformationcontent1releasesmarket

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoubleVerify

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In DoubleVerify To Contact Him Directly To...

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Evaluating the True Value of a Financial Adviser for Strategic Asset Management

**The Systematic Approach to Achieving Financial Independence** Investing in low-cost mutual funds can be an effective strategy for individuals seeking to manage their own financial...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Meta Develops Superintelligence Lab: Assessing AI’s Impact on Quantitative Models

**Title: Meta's Strategic Investment in AI: A Quantitative Perspective** **Introduction** Meta Platforms Inc. has announced a strategic $14.3 billion investment in a new artificial intelligence (AI)...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

No KYC. 100x Leverage. $50 Welcome Bonus. Crypto Futures Trading Made Easy on BexBack.

SINGAPORE, June 14, 2025 (GLOBE NEWSWIRE) -- With the price of Bitcoin fluctuating around $100,000, many analysts predict that the cryptocurrency market will remain in a state of high volatility for a long time. Holding spot positions may struggle to generate short-term profits in such conditions. As a result, 100x leverage futures trading has become the preferred tool for seasoned investors looking to maximize potential gains in this volatile market. BexBack Exchange is ramping up its efforts to offer traders unmatched promotional packages. The platform now features a 100% deposit bonus, a $50 welcome bonus for new users, and 100x leverage on cryptocurrency trading, providing exceptional opportunities for investors.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Nuclear Air Filtration for HVAC Managers: Why the Nuclear Comeback Demands Next-Gen Filtration Standards

The Big Reveal: What HVAC Managers Must Know About High-Performance Filtration. Camfil Nuclear air filters are used for containment control during dismantling or maintenance work at a nuclear sites. 
The Big Reveal:  What HVAC Managers Must Know About High-Performance Filtration. Camfil Nuclear air filters are used for containment control during dismantling or maintenance work at a nuclear sites.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRisk

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers